Patents by Inventor Miguel A. Medina
Miguel A. Medina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100267827Abstract: The present invention is related to a family of phenyl-prenyl-ether derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or 5 Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.Type: ApplicationFiled: August 1, 2007Publication date: October 21, 2010Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Pilar Munoz Ruiz, Javier Lopez Ogalla, Laura Rubio Arrieta, Esther Garcia Palomero, Pablo Garcia Fernandez, Celia De Austria De Luque, Elena Delgado Hernandez, Paola Usan Egea, Rita Valenzuela Liminana, Jorge Sanchez-Quesada
-
Publication number: 20100240692Abstract: The present invention relates to a new family of [1,10]-phenantroline derivatives of formula (I), which are useful for the treatment or profilaxis of a neurodegenerative or haematological disease or condition, their use as a medicament, especially for treating a treatment neurodegenerative or haematological disease or condition, and a pharmaceutical composition comprising the compounds.Type: ApplicationFiled: June 11, 2008Publication date: September 23, 2010Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Jorge Sanchez-Quesada, Mercedes Alonso Cascon, Laura Rubio Arrieta, Esther Garcia Palomero, Paola Usan Egea
-
Publication number: 20100048635Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.Type: ApplicationFiled: July 28, 2006Publication date: February 25, 2010Applicants: Neuropharma, S.A., Instituto Biomar, S.A.Inventors: Ana Martinez Gil, Paola Egea, Miguel Medina Padilla, Esther Palomero, Julia Perez Baz, Rosa Fernandez Chimeno, Antonio Medarde Fernandez, Librada Canedo Hernandez, Francisco Romero Millan, Ana Castro Morera, Mercedes Alonso Cascon, Jorge Sanchez Quesada
-
Publication number: 20100041665Abstract: The present invention is related to a family of N-phenyl-prenylamine derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present invention is directed to the use of the compounds in the manufacture of a medicament for the treatment and/or prevention of a cognitive, neurodegenerative or neuronal disease or disorder.Type: ApplicationFiled: August 1, 2007Publication date: February 18, 2010Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Pilar Munoz Ruiz, Javier Lopez Ogalla, Esther Garcia Palomero, Celia De Austria De Luque, Paola Usan Egea, Rita Valenzuela Liminana, Pablo Garcia Fernandez, Elena Delgado Hernandez, Daniel Ignacio Perez Fernandez
-
Publication number: 20090233971Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.Type: ApplicationFiled: April 22, 2009Publication date: September 17, 2009Applicant: Noscira, S.A.Inventors: Miguel Medina Padilla, Mercedes Alonso Cascon, Isabel Dorronsoro Diaz, Ana Martinez Gil, Gema Panizo del Pliego, Ana Fuertes Huerta, Maria Jose Perez Puerto
-
Publication number: 20090221647Abstract: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I), for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.Type: ApplicationFiled: April 27, 2007Publication date: September 3, 2009Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Ester Martin Aparicio, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Maria Del Monte Millan
-
Publication number: 20090192204Abstract: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I) for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.Type: ApplicationFiled: April 27, 2007Publication date: July 30, 2009Applicant: NOSCIRA, S.A.Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Ester Martin Aparicio, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Maria Del Monte Millan
-
Publication number: 20090124686Abstract: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3?, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.Type: ApplicationFiled: July 28, 2006Publication date: May 14, 2009Applicant: NEUROPHARMA, S.A.Inventors: Ana Martinez Gil, Miguel Medina Padilla, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Ana Castro Morera, Ester Martin Aparicio
-
Patent number: 7531561Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.Type: GrantFiled: April 5, 2005Date of Patent: May 12, 2009Assignee: Noscira, S.A.Inventors: Miguel Medina Padilla, Mercedes Alonso Cascón, Isabel Dorronsoro Díaz, Ana Martínez Gil, Gema Panizo del Pliego, Ana Fuertes Huerta, María José Pérez Puerto
-
Publication number: 20090069430Abstract: The invention is directed to a compound of formula (I) Having VDCC blocking activity. These compounds are useful for the treatment of a series of human diseases and conditions, especially cognitive or neurodegenerative diseases or conditions.Type: ApplicationFiled: June 16, 2008Publication date: March 12, 2009Applicant: NEUROPHARMA, S.A.Inventors: Ana MARTINEZ GIL, Ana Castro Morera, Miguel Medina Padilla, Pilar Munoz Ruiz, Laura Rubio Arrieta, Esther Garcia Palomero, Celia De Austria De Luque, Jorge Sanchez-Quesada, Daniel Ignacio Perez Fernandez, Javier Lopez Ogalla, Diana Alonso Gordillo
-
Publication number: 20080275088Abstract: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.Type: ApplicationFiled: July 28, 2006Publication date: November 6, 2008Applicants: NEUROPHARMA, S.A., INSTITUTO BIOMAR, S.A.Inventors: Ana Martinez Gil, Paola Usan Egea, Miguel Medina Padilla, Esther Garcia Palomero, Julia Perez Baz, Rosa Isabel Fernandez Chimeno, Antonio Medarde Fernandez, Librada Maria Canedo Hernandez, Francisco Romero Millan, Ana Castro Morera, Mercedes Alonso Cascon, Jorge Sanchez Quesada
-
Publication number: 20080119521Abstract: The invention provides butyrylcholinesterase inhibitors of formula (I), which contain an heterocyclic moiety and a 4 piperidine moiety with a linker in between. The compounds show a very high activity and selectivity towards BuChE, making them useful for the treatment and/or prophylaxis of cognitive disorders and/or neurodegenerative disorders.Type: ApplicationFiled: May 27, 2005Publication date: May 22, 2008Inventors: Ana Martinez Gil, Laura Rubio Arrieta, Pilar Muñoz Ruiz, Isabel Dorronsoro Diaz, Esther Garcia Palomero, Maria del Monte Millan, Miguel Medina Padilla
-
Publication number: 20080039513Abstract: The invention provides compounds having a spiro heterocyclic unit connected through a linker of a certain length to another spiro cycle, an imidazole ring or an amide group. Some of these compounds have been obtained from Aplysinia cavernicola and a mixture of Aplysina fulva and Oceanapia. The compounds exhibit VDCC blocker activity; some also show acetylcholinesterase and butyrylcholinesterase inhibition activities. Therefore they are useful in the treatment of cognitive and neurodegenerative disorders, such as brain ischemia, stroke, cognitive disorders as senile dementia, cerebrovascular dementia, mild recognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimers's disease or condition, or prion disease as Creutzfeld-Jakob disease or Gerstmann-Straussler-Scheinker disease.Type: ApplicationFiled: June 17, 2005Publication date: February 14, 2008Inventors: Ana Martinez Gil, Diana Alonso Gordillo, Isabel Dorronsoro Diaz, Esther Garcia Palomero, Celia De Austria De Luque, Paola Usan Egea, Maria Del Monte Millan, Miguel Medina Padilla
-
Patent number: 6557800Abstract: A cargo handling system for cargo compartments utilizes a cargo container which rides along restraining guide rails and on top of rollers situated within and projecting slightly above structural members which are attached to roller possessing cross tracks. The cargo handling system utilizes an omni directional panel just inside the cargo door to facilitate loading, unloading, and rotational alignment of the cargo containers with the guide rails and rollers. Cargo locks situated within the roller channels and the omni directional panel secure the cargo containers in a longitudinal direction of the aircraft fuselage while a side latch within the omni directional panel secures cargo containers vertically, and in a lateral direction. An automatic anti-rollout restraint prevents the cargo container from rolling out of the aircraft while the cargo containers are being loaded or unloaded. Optionally, a power drive unit automatically moves the cargo containers along the rollers.Type: GrantFiled: September 26, 2001Date of Patent: May 6, 2003Assignee: The Boeing CompanyInventors: Miguel A. Medina, Alonzo Royal, Rosario Saggio, William N. Korb, Behrooz Afghani, Karlton K. Okamoto
-
Publication number: 20030057326Abstract: A cargo handling system for cargo compartments utilizes a cargo container which rides along restraining guide rails and on top of rollers situated within and projecting slightly above structural members which are attached to roller possessing cross tracks. The cargo handling system utilizes an omni directional panel just inside the cargo door to facilitate loading, unloading, and rotational alignment of the cargo containers with the guide rails and rollers. Cargo locks situated within the roller channels and the omni directional panel secure the cargo containers in a longitudinal direction of the aircraft fuselage while a side latch within the omni directional panel secures cargo containers vertically, and in a lateral direction. An automatic anti-rollout restraint prevents the cargo container from rolling out of the aircraft while the cargo containers are being loaded or unloaded. Optionally, a power drive unit automatically moves the cargo containers along the rollers.Type: ApplicationFiled: September 26, 2001Publication date: March 27, 2003Inventors: Miguel A. Medina, Alonzo Royal, Rosario Saggio, William N. Korb, Behrooz Afghani, Karlton K. Okamoto
-
Patent number: 6213784Abstract: Provides an electrical connector for the cathodic protection of a metallic surface that is subject to corrosion. A layer of insulative adhesive, layer of conductive adhesive and a suction cup are provided so as to permit the electrical connector to be adhesively secured to the metallic surface. This permits cathodic protection of the metallic surface under all corrosive conditions and provides good conductivity.Type: GrantFiled: May 15, 2000Date of Patent: April 10, 2001Assignee: National Starch and Chemical Investment Holding CorporationInventors: Joseph Cairoli, Carl Hawkins, Luis Miguel Medina